Changeflow GovPing Pharma & Drug Safety BacPROTACs for Targeted Protein Degradation in ...
Routine Notice Added Final

BacPROTACs for Targeted Protein Degradation in Bacteria

Favicon for changeflow.com ChangeBridge: Patent Apps - Therapeutics (A61P)
Published
Detected
Email

Summary

Washington University published patent application US20260091118A1 for bivalent agents (BacPROTACs) designed for targeted protein degradation in mycobacteria and other bacteria, including methods for reducing antibiotic resistance. The application (No. 19312129, filed August 27, 2025) covers compositions and methods for treating antibiotic-resistant bacterial infections.

What changed

Washington University filed patent application US20260091118A1 disclosing bivalent BacPROTAC agents capable of targeted protein degradation in mycobacteria and other bacteria. The application claims methods for reducing antibiotic resistance associated with bacterial infections and methods of treating antibiotic-resistant bacterial infections. Inventors include Timothy Wencewicz, Emily Williford, Helen Blaine, and Christina Stallings.

This is a patent application publication with no regulatory compliance requirements. Companies developing antibiotics or degradation-based therapeutics may wish to review the claims to assess potential freedom-to-operate considerations. The filing date was August 27, 2025, with publication on April 2, 2026.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

Methods for Preparation and Use of BacPROTACs for Targeted Protein Degradation in Mycobacteria and Other Bacteria

Application US20260091118A1 Kind: A1 Apr 02, 2026

Assignee

Washington University

Inventors

Timothy Wencewicz, Emily Williford, Helen Blaine, Christina Stallings

Abstract

Among the various aspects of the present disclosure is the provision of bivalent agents for targeted protein degradation. Also disclosed are compositions including the bivalent agents and methods of use, including methods of reducing antibiotic resistance associated with an antibiotic-resistant bacterial infection and methods of treating an antibiotic-resistant bacterial infection.

CPC Classifications

A61K 47/552 A61K 47/543 A61K 47/60 A61P 31/04

Filing Date

2025-08-27

Application No.

19312129

View original document →

Named provisions

Abstract Methods for Preparation and Use of BacPROTACs Methods of Reducing Antibiotic Resistance Methods of Treating Antibiotic-Resistant Bacterial Infection

Get daily alerts for ChangeBridge: Patent Apps - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260091118A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology 6211 Healthcare Providers
Activity scope
Patent Claims Drug Development Antibiotic Research
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Legal
Topics
Pharmaceuticals Intellectual Property Antibiotic Resistance

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Therapeutics (A61P) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.